Defendants in the multidistrict litigation over weight-loss drugs like Ozempic are asking the court to throw out plaintiffs’ claims that the defendants deceived consumers and doctors about the safety of the medications.

In a memorandum accompanying a Jan. 24 motion to dismiss, drug makers Novo Nordisk and Eli Lilly contended that the majority of the plaintiffs’ allegations were “extraneous to the core issues in the litigation, inadequately pleaded or plainly foreclosed.”